T‐cell modulation by checkpoint inhibitors that target the PD‐1/PD‐L1 interaction, and thereby release the breaks of CD8+ cytotoxic T lymphocytes (CTLs), have shown unprecedented effects in several cancers.3 The gene discussed is CD274; the disease is cancer.